A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2022-10-01
Adverse events
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-15 (study day 4); relationship: N
Grade 1 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2023-01-19 (study day 100); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-22 (study day 162); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-24 (study day 164); relationship: N
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-07-23 (study day 285); relationship: N
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-08-14 (study day 307); relationship: not assessed
Data queries
No data queries.